The pathogenic potential of autoreactive antibodies in rheumatoid arthritis

Seminars in Immunopathology

Volumn 36, Issue 3, 2014, Pages 313-325

  Bax, Marieke ^a   Huizinga, Tom W J ^a   Toes, René E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ACPAs; Anti CarP antibodies; Autoantibodies; Autoreactive B cells; Posttranslational modifications; Rheumatoid arthritis

Indexed keywords

ANTIPERINUCLEAR FACTOR; AUTOANTIBODY; CITRULLINATED PROTEIN ANTIBODY; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KERATIN ANTIBODY; PAD4 ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ALLELE; ANTIBODY AND IMMUNOGLOBULIN STRUCTURE, FUNCTION AND PRODUCTION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTHRALGIA; ARTHRITIS; B LYMPHOCYTE; CARBAMOYLATION; CITRULLINATION; CROSS REACTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GLYCOSYLATION; HLA DRB1 GENE; HLA SYSTEM; HUMAN; ISOTYPE SWITCHING; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; BIOLOGICAL MARKERS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84902328518     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-014-0429-5     Document Type: Review

References (88)

1. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094-1108. doi:10.1016/S0140-6736(10)60826-4
2. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903-911. doi:10.1016/S0140-6736(01)06075-5 (Pubitemid 32900579)
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (Pubitemid 18091653)
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: doi:10.1136/ard.2010.138461
5. Klareskog L, Padyukov L, Alfredsson L (2007) Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 19:49-54. doi:10.1097/BOR.0b013e32801127c8 (Pubitemid 44885727)
6. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3):S265-S272
7. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, Silman AJ (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30-37. doi:10.1002/1529- 0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B (Pubitemid 30368210)
8. Bowes J, Barton A (2008) Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 47:399-402. doi:10.1093/rheumatology/ ken005
9. Imboden JB (2009) The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 4:417-434. doi:10.1146/annurev.pathol.4.110807.092254
10. Astorga GP, Williams RC Jr (1969) Altered reactivity in mixed lymphocyte culture of lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 12:547-554
11. Stastny P (1976)Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 57:1148-1157. doi:10.1172/JCI108382
12. Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-1213 (Pubitemid 18005792)
13. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433-3438. doi:10.1002/art.21385 (Pubitemid 41612209)
14. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J, Kern M, Criswell LA, Albani S, Nelson JL, Clegg DO, Pope R, Schroeder HW Jr, Bridges SL Jr, Pisetsky DS, Ward R, Kastner DL, Wilder RL, Pincus T, Callahan LF, Flemming D, Wener MH, Gregersen PK (2001) A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 68:927-936 (Pubitemid 32289739)
15. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402. doi:10.1038/ng1206 (Pubitemid 36935332)
16. Bax M, van Heemst J, Huizinga TW, Toes RE (2011) Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 63:459-466. doi:10.1007/s00251- 011-0528-6
17. Zhernakova A, van Diemen CC, Wijmenga C (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 10:43-55. doi:10.1038/nrg2489
18. van der Woude D, Lie BA, Lundstrom E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, Verduijn W, Nordang GB, Alfredsson L, Klareskog L, Pascual-Salcedo D, Gonzalez-Gay MA, Lopez-Nevot MA, Valero F, Roep BO, Huizinga TW, Kvien TK, Martin J, Padyukov L, de Vries RR, Toes RE (2010) Protection against anticitrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLADRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 62:1236-1245. doi:10.1002/art.27366
19. Frankline EC, Holman HR, Muller-Eberhard HJ, Kunkel HG (1957) An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 105:425-438
20. Nienhuis RL, Mandema E (1964) A new serumfactor in patientswith rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23:302-305
21. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ (1979) Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2:97-99 (Pubitemid 9219480)
22. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672-2679. doi:10.1172/JCI117969
23. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585-594 (Pubitemid 29018970)
24. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, Levarht NE, van der Helm-van Mil AH, Cerami A, Huizinga TW, Toes RE, Trouw LA (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108:17372-17377. doi:10.1073/pnas.1114465108
25. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A (2013) Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 5:186ra65. doi:10.1126/ scitranslmed.3005370
26. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ (2013) Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 123:1773-1783. doi:10.1172/JCI65292
27. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, Catrina AI (2006) Citrullination is an inflammation dependent process. Ann Rheum Dis 65:1219-1222. doi:10.1136/ard.2005.049403
28. Ireland J, Herzog J, Unanue ER (2006) Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J Immunol 177:1421-1425 (Pubitemid 44092474)
29. Ireland JM,Unanue ER (2011)Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 208:2625-2632. doi:10.1084/jem.20110640
30. Cantaert T, Teitsma C, Tak PP, Baeten D (2013) Presence and role of anti-citrullinated protein antibodies in experimental arthritis models. Arthritis Rheum 65:939-948. doi:10.1002/art.37839
31. Vossenaar ER, van Boekel MA, van Venrooij WJ, Lopez-Hoyoz M, Merino J, Merino R, Joosten LA (2004) Absence of citrulline-specific autoantibodies in animal models of autoimmunity. Arthritis Rheum 50:2370-2372. doi:10.1002/art.20296 (Pubitemid 38924417)
32. Jaisson S, Pietrement C, Gillery P (2011) Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 57:1499-1505. doi:10.1373/clinchem.2011.163188
33. Wynckel A, Randoux C, Millart H, Desroches C, Gillery P, Canivet E, Chanard J (2000) Kinetics of carbamylated haemoglobin in acute renal failure. Nephrol Dial Transplant 15:1183-1188 (Pubitemid 30487795)
34. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176-1184. doi:10.1038/nm1637 (Pubitemid 47530630)
35. Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg O (2009) Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis 68:249-252. doi:10.1136/ard.2008.094490
36. Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, Gao P, Scott WW Jr, El-Gabalawy H, Casciola-Rosen L, Barnes KC, Bathon JM, Rosen A (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 58:1958-1967. doi:10.1002/art.23596 (Pubitemid 351988087)
37. Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K (2005) Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 34:212-215 (Pubitemid 40978642)
38. Zhao J, Zhao Y, He J, Jia R, Li Z (2008) Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 35:969-974 (Pubitemid 351813138)
39. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273-281. doi:10.1172/JCI1316 (Pubitemid 28058927)
40. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, vanVenrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163. doi:10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3 (Pubitemid 30368225)
41. Ioan-Facsinay A, el Bannoudi H, Scherer HU, van der Woude D, Menard HA, Lora M, Trouw LA, Huizinga TW, Toes RE (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anticitrullinated protein antibodies and contain overlapping and nonoverlapping reactivities. Ann Rheum Dis 70:188-193. doi:10.1136/ard.2010.131102
42. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, Serre G, Burkhardt H, Thunnissen MM, Holmdahl R (2009) Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 206:449-462. doi:10.1084/jem.20081862
43. Amara K, Steen J, Murray F, Morbach H, Fernandez-Rodriguez BM, Joshua V, Engstrom M, Snir O, Israelsson L, Catrina AI, Wardemann H, Corti D, Meffre E, Klareskog L, Malmstrom V (2013) Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 210:445-455. doi:10.1084/jem.20121486
44. van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, van Schaardenburg D (2011) Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 63:3226-3233. doi:10.1002/art.30537
45. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TW, Toes RE, Pruijn GJ (2010) Epitope spreading of the anticitrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69:1554-1561. doi:10.1136/ard.2009.124537
46. Willemze A, Shi J, Mulder M, Stoeken-Rijsbergen G, Drijfhout JW, Huizinga TW, Trouw LA, Toes RE (2013) The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Ann Rheum Dis 72:1059-1063. doi:10.1136/annrheumdis-2012-202747
47. Fisher BA, Plant D, Brode M, van Vollenhoven RF, Mathsson L, Symmons D, Lundberg K, Ronnelid J, Venables PJ (2011) Antibodies to citrullinated alpha-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 70:1095-1098. doi:10.1136/ard.2010.138909
48. Willemze A, Bohringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, van der Helm-van Mil AH, Huizinga TW, Toes RE, Trouw LA (2012) The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 71:268-274. doi:10.1136/annrheumdis-2011-200421
49. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, de Vries RR, Toes RE (2005) Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 52:3058-3062. doi:10.1002/art.21302 (Pubitemid 41447086)
50. Scherer HU, van der Woude D, Willemze A, Trouw LA, Knevel R, Syversen SW, van der Linden MP, Lie B, Huizinga TW, van der Heijde DM, van der Helm-van Mil AH, Kvien TK, Toes RE (2011) Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis 70:1461-1464. doi:10.1136/ard. 2010.146506
51. Ioan-Facsinay A, Willemze A, Robinson DB, Peschken CA, Markland J, van der Woude D, Elias B, Menard HA, Newkirk M, Fritzler MJ, Toes RE, Huizinga TW, El-Gabalawy HS (2008) Marked differences in fine specificity and isotype usage of the anticitrullinated protein antibody in health and disease. Arthritis Rheum 58:3000-3008. doi:10.1002/art.23763
52. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Ronnelid J, Rantapaa-Dahlqvist S (2011) Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 13:R13. doi:10.1186/ar3237
53. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54:3799-3808. doi:10.1002/art.22279 (Pubitemid 44955880)
54. van der Woude D, Syversen SW, van der Voort EI, Verpoort KN, Goll GL, van der Linden MP, van der Helm-van Mil AH, van der Heijde DM, Huizinga TW, Kvien TK, Toes RE (2010) The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 69:1110-1116. doi:10.1136/ard.2009.116384
55. Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jolvan der Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA (2011) Anti-citrullinated protein antibodies have a low avidity comparedwith antibodies against recall antigens. Ann Rheum Dis 70:373-379. doi:10.1136/ard.2010.135509
56. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452-457 (Pubitemid 16238456)
57. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673. doi:10.1126/science.1129594 (Pubitemid 44201145)
58. Scherer HU,Wang J, Toes RE, van derWoude D, Koeleman CA, de Boer AR, Huizinga TW, Deelder AM, Wuhrer M (2009) Immunoglobulin 1 (IgG1) Fc-glycosylation profiling of anticitrullinated peptide antibodies from human serum. Proteomics Clin Appl 3:106-115. doi:10.1002/prca.200800098
59. Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, Haupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M, Toes RE (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62:1620-1629. doi:10.1002/art.27414
60. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, Deelder AM, Huizinga TW, Toes RE, Wuhrer M (2011) Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 10:M110. doi:10.1074/mcp.M110. 004655
61. Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, Huizinga TW, Wuhrer M, van Schaardenburg D, Toes RE, SchererHU(2013) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203565
62. Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, Bokarewa M (2010) Carbamylation-dependent activation of Tcells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 184:6882-6890. doi:10.4049/jimmunol.1000075
63. Turunen S, Koivula MK, Risteli L, Risteli J (2010) Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum 62:3345-3352. doi:10.1002/art.27644
64. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196-201. doi:10.1136/ard.2003.019992 (Pubitemid 40193611)
65. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709-715. doi:10.1002/art.20044 (Pubitemid 38326168)
66. Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans BA, van Schaardenburg D (2010) Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 69:490-494. doi:10.1136/ard.2008.105759
67. van de Stadt LA, van der Horst AR, de Koning MH, Bos WH, Wolbink GJ, van de Stadt RJ, Pruijn GJ, Dijkmans BA, van Schaardenburg D, Hamann D (2011) The extent of the anticitrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 70:128-133. doi:10.1136/ard.2010.132662
68. Krabben A, Stomp W, van der Heijde DM, van Nies JA, Bloem JL, Huizinga TW, Reijnierse M, van der Helm-van Mil AH (2013) MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Ann Rheum Dis 72:1540-1544. doi:10.1136/annrheumdis-2012- 202628
69. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, Van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380-386. doi:10.1002/art.20018 (Pubitemid 38198821)
70. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA (2012) Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 64:1323-1328. doi:10.1002/art.33489
71. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, Huizinga TW, Toes RE (2009) Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 60:1923-1931. doi:10.1002/art.24622
72. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 58:678-688. doi:10.1002/art.23284 (Pubitemid 351364865)
73. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791-1802. doi:10.1172/JCI60975
74. van Oosterhout M, Sont JK, Bajema IM, Breedveld FC, van Laar JM (2006) Comparison of efficacy of arthroscopic lavage plus administration of corticosteroids, arthroscopic lavage plus administration of placebo, and joint aspiration plus administration of corticosteroids in arthritis of the knee: a randomized controlled trial. Arthritis Rheum 55:964-970. doi:10.1002/art.22340 (Pubitemid 44917472)
75. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Bozic B, Pruijn GJ (2013) The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 65:69-80. doi:10.1002/art.37720
76. Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EW, van der Helm-van Mil AH, van Schaardenburg D, Huizinga TW, Toes RE, Trouw LA (2013) Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202615
77. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 207:1853-1862. doi:10.1084/jem.20100239
78. Pratesi F, Dioni I, Tommasi C, Alcaro MC, Paolini I, Barbetti F, Boscaro F, Panza F, Puxeddu I, Rovero P, Migliorini P (2013) Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis. doi:10.1136/annrheumdis-2012- 202765
79. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, Friday S, Li S, Patel RM, Subramanian V, Thompson P, Chen P, Fox DA, Pennathur S, Kaplan MJ (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5:178ra40. doi:10.1126/scitranslmed.3005580
80. Kolfenbach JR, Deane KD, Derber LA, O'Donnell CI, Gilliland WR, Edison JD, Rosen A, Darrah E, Norris JM, Holers VM (2010) Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum62:2633-2639. doi:10.1002/art.27570
81. Ferucci ED, Darrah E, Smolik I, Choromanski TL, Robinson DB, Newkirk MM, Fritzler MJ, Rosen A, El-Gabalawy HS (2013) Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous north american populations. J Rheumatol 40:1523-1528. doi:10.3899/jrheum.130293
82. Kerkman PF, Rombouts Y, van der Voort EI, Trouw LA, Huizinga TW, Toes RE, Scherer HU (2013) Circulating plasmablasts/ plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202893
83. Doorenspleet ME, Klarenbeek PL, de Hair MJ, van Schaik BD, Esveldt RE, van Kampen AH, Gerlag DM, Musters A, Baas F, Tak PP, de Vries N (2013) Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann Rheum Dis. doi:10.1136/annrheumdis- 2012-202861
84. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424-1432. doi:10.1002/art.22525 (Pubitemid 46764069)
85. Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW, van der Helm-van Mil AH (2008) Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 67:1194-1195. doi:10.1136/ard.2008.088070
86. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF (2008) Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 58:1293-1298. doi:10.1002/art.23439 (Pubitemid 351705918)
87. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le LX, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, openlabel study. Arthritis Rheum 63:933-938. doi:10.1002/art.30233
88. Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ (2012) Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis. J Rheumatol 39:929-932. doi:10.3899/jrheum.111315